Dr. Pfleger Arzneimittel GmbH is a medium-sized pharmaceutical company with over 390 employees and a sales turnover of €92,5 million in 2020. Dr. Pfleger markets over 60 non-prescription and prescription medicines for indications in urology, gyneacology, dermatology and areas of self-medication in Germany and selected territories world-wide. A milestone for the company’s success was its development of the spasmolytic drug Spasmex®. Other important medicines include Bicalutin®, for the treatment of advanced prostate carcinomas, and Urtimed®, for allergic rhinitis and urticaria. The pain reliever Neuralgin®, ipalat® throat pastilles, the antimycotic drug Mykosert®, and the extensive Bio-H-Tin® range of products for hair and nails, have established themselves as strong brands in German pharmacies. With the launch of Elmiron® Dr. Pfleger has the first approved medicine in Germany for the treatment of chronic bladder pain (interstitial cystitis). Dr. Pfleger exports to around 40 countries, where marketing & sales is carried out by competent local partners. At the state-of-the-art production site in Bamberg, Germany, Dr. Pfleger does not just manufacture its own products, but also others under contract for reputable domestic and overseas pharmaceutical companies. The financial surpluses generated by the company are passed onto the Doktor Robert Pfleger-Stiftung. The foundation is supporter of medical research and sponsor of the Robert Pfleger-Forschungspreis (research prize). Furthermore the Doktor Robert Pfleger-Stiftung fulfills social charitable purposes, in particular in the field of youth and elderly care.
